[go: up one dir, main page]

PE20010647A1 - Moduladores de receptores de retinoide x (rxr) con perfil farmacologico mejorado - Google Patents

Moduladores de receptores de retinoide x (rxr) con perfil farmacologico mejorado

Info

Publication number
PE20010647A1
PE20010647A1 PE2000000952A PE0009522000A PE20010647A1 PE 20010647 A1 PE20010647 A1 PE 20010647A1 PE 2000000952 A PE2000000952 A PE 2000000952A PE 0009522000 A PE0009522000 A PE 0009522000A PE 20010647 A1 PE20010647 A1 PE 20010647A1
Authority
PE
Peru
Prior art keywords
alkyl
gluces
retinoid
together form
ring
Prior art date
Application number
PE2000000952A
Other languages
English (en)
Inventor
Robert J Ardecky
John S Tyhonas
Marcus F Boehm
Lawrence G Hamann
Christopher M Mapes
Anthony W Thompson
Jyun-Hung Chen
Pierre-Yves Michelys
Todd K Jones
Amy L Faulkner
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20010647A1 publication Critical patent/PE20010647A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA 1 O 2 DONDE R1 ES H, F, Cl, Br,I ; R2 A R4 SON H, ALQUILO C1-C5, HETEROALQUILO, HALOALQUILO C1-C5, CICLOALQUILO C3-C5, ALQUENILO C2-C5, HETEROALQUENILO, ALQUINILO, ENTRE OTROS; R2 Y R4 SON NR10R11; R2 Y R3 O R3 Y R4 JUNTOS FORMAN UN ANILLO CARBOCICLICO O HETEROCICLICO DE 5-7 MIEMBROS; R5 Y R6 SON H, F, Cl, Br, I, CN, NH2, OH, SH, ALQUILO C1-C3, ENTRE OTROS; R5 Y R6 JUNTOS FORMAN UNA ANILLO CARBOCICLICO, HETEROCICLICO DE 3-8 MIEMBROS; R7 ES ALQUILO C1-C5, ALQUENILO C2-C5, HALOALQUILO C2-C5; R8 ES H, F, Cl, Br, I, CN, ALQUILO C1-C3, ENTRE OTROS; R9 ES H, HALOGENO; R1O Y R11 SON H, ALQUILO Y JUNTOS FORMAN UN ANILLO DE CICLOALQUILO DE 5-6 MIEMBROS; R12 ES H; Y ES NR12. UN COMPUESTO PREFERIDO ES L2, L3, ENTRE OTROS. SE REFIERE TAMBIEN AL PROCESO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN AGONISTA PPARO, PPARþ. LOS COMPUESTOS DE FORMULA 1 Y 2 MODULAN LA ACTIVIDAD BIOLOGICA DE LOS RECEPTORES DE RETINOIDE X, TIENEN ACCION SOBRE LA PROLIFERACION CELULAR Y PUEDEN SER UTILES EN EL TRATAMIENTO DE CANCER, LEUCEMIA, ENFERMEDADES OCULARES, CARDIOVASCULARES, REDUCIR LOS NIVELES DE GLUCOSA EN SANGRE SIN ALTERAR LOS NIVELES DE TRIGLICERIDOS, MODULAR EL METABOLISMO DE LOS LIPIDOS, INCREMENTAR LOS NIVELES DE HDL
PE2000000952A 1999-09-14 2000-09-14 Moduladores de receptores de retinoide x (rxr) con perfil farmacologico mejorado PE20010647A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15389099P 1999-09-14 1999-09-14

Publications (1)

Publication Number Publication Date
PE20010647A1 true PE20010647A1 (es) 2001-06-23

Family

ID=22549155

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000952A PE20010647A1 (es) 1999-09-14 2000-09-14 Moduladores de receptores de retinoide x (rxr) con perfil farmacologico mejorado

Country Status (8)

Country Link
US (2) US6593493B1 (es)
EP (1) EP1216221A2 (es)
JP (1) JP2003529545A (es)
AU (1) AU7586600A (es)
CA (1) CA2383565A1 (es)
CO (1) CO5200852A1 (es)
PE (1) PE20010647A1 (es)
WO (1) WO2001019770A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
WO1999005161A1 (en) 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
EP1093362A1 (en) * 1998-06-12 2001-04-25 Ligand Pharmaceuticals Incorporated Treatment of anti-estrogen resistant breast cancer using rxr modulators
AU2002255732B2 (en) * 2001-03-14 2006-03-09 Eli Lilly And Company Fluorinated trienes and their use as RXR modulators
MXPA03007779A (es) * 2001-03-14 2004-11-12 Lilly Co Eli Moduladores de los receptores de retinoides x.
CA2452541A1 (en) * 2001-07-20 2003-01-30 Eli Lilly And Company (pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators
WO2003055473A1 (en) * 2001-12-21 2003-07-10 Charlotte Mecklenburg Hospital Authority Doing Business As Carolinas Medical Center Regulation of nad(p)h oxidase growth and transcription in melanoma cells
US7250442B2 (en) 2002-03-15 2007-07-31 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
US6759547B1 (en) * 2003-01-14 2004-07-06 Allergan, Inc. 5,6,7,8-tetrahydronaphthalen-2-yl 2,6-difluoroheptatrienoic acid derivatives having serum glucose reducing activity
US7019034B2 (en) 2003-01-28 2006-03-28 Allergan, Inc. Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals
US6759546B1 (en) 2003-02-04 2004-07-06 Allergan, Inc. 3,5-di-iso-propyl-heptatrienoic acid derivatives having serum glucose reducing activity
US6884820B2 (en) 2003-04-03 2005-04-26 Allergan, Inc. 5,6,7,8-tetrahydronaphthalen-2-yl-7-fluoroalkyl-heptatrienoic acid derivatives having serum glucose reducing activity
US6734193B1 (en) 2003-06-03 2004-05-11 Allergan, Inc. (1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
US6887896B1 (en) 2003-10-29 2005-05-03 Allergan, Inc. 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity
CA2569691C (en) 2004-06-23 2010-08-17 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivatives
US9050310B2 (en) * 2004-06-25 2015-06-09 Minas Theodore Coroneo Treatment of ocular lesions
EP1621191A1 (en) * 2004-07-29 2006-02-01 Werner Bollag Treatment of inflammatory diseases by RXR Antagonists
US20070021612A1 (en) * 2004-11-04 2007-01-25 University Of Notre Dame Du Lac Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
WO2006052860A2 (en) 2004-11-04 2006-05-18 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation
AU2005314039B2 (en) * 2004-12-08 2008-01-31 Revision Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
US20060204474A1 (en) * 2005-02-25 2006-09-14 Coroneo Minas T Treatment of epithelial layer lesions
EP1937244B1 (en) 2005-09-30 2018-07-25 Io Therapeutics, LLC Treatment of cancer with specific rxr agonists
AU2012352149B2 (en) 2011-12-13 2017-06-01 Io Therapeutics, Inc. Autoimmune disorder treatment using RXR agonists
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
JP5877466B2 (ja) * 2012-02-29 2016-03-08 国立大学法人 岡山大学 テルペノイド由来レチノイド化合物
WO2014164608A1 (en) * 2013-03-13 2014-10-09 Avon Products, Inc Cosmetic use of salicylic acid derivatives
KR102377635B1 (ko) * 2013-07-17 2022-03-24 오츠카 세이야쿠 가부시키가이샤 시아노트리아졸 화합물
US11045441B2 (en) 2015-10-13 2021-06-29 Wisconsin Alumni Research Foundation Use of retinoic acid and analogs thereof to treat central neural apneas
WO2017075610A1 (en) * 2015-10-31 2017-05-04 Io Therapeutics, Inc. Treatment of nervous system disorders using thyroid hormone neutral doses of rxr agonists
CN108289958A (zh) 2015-10-31 2018-07-17 Io治疗公司 使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱
KR20180121983A (ko) 2016-03-10 2018-11-09 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 근육 질환의 치료
CN109310769B (zh) 2016-03-10 2022-07-05 Io治疗公司 用rxr激动剂与甲状腺激素的组合的自身免疫疾病的治疗
WO2019060600A1 (en) 2017-09-20 2019-03-28 Io Therapeutics, Inc. TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
KR20240115316A (ko) 2021-12-07 2024-07-25 아이오 테라퓨틱스, 인크. 약물 내성 her2+ 암 치료에서의 rxr 작용제의 용도
MX2024006978A (es) 2021-12-07 2024-07-19 Io Therapeutics Inc Uso de un agonista de rxr y taxanos en el tratamiento de cáncer her2+.

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH590274A5 (es) 1970-03-16 1977-07-29 Hoffmann La Roche
DE2038106A1 (de) 1970-07-31 1972-02-10 Henkel & Cie Gmbh Aktivatoren fuer Perverbindungen
US3979394A (en) 1970-12-11 1976-09-07 Agfa-Gevaert N.V. Duplo quinoline compounds
GB1379387A (en) 1970-12-11 1975-01-02 Agfa Gevaert Photoconductive recording materials
GB1400993A (en) 1971-11-10 1975-07-16 Agfa Gevaert Electrophotographic material
BE795696A (nl) 1972-02-28 1973-08-21 Agfa Gevaert Nv Voor warmte gevoelige materialen
US3936461A (en) 1973-09-24 1976-02-03 Warner-Lambert Company Substituted 4-benzylquinolines
US3993656A (en) 1974-11-19 1976-11-23 Merck & Co., Inc. 1,8-Naphthyridine compounds
IE43079B1 (en) 1975-03-20 1980-12-17 Ici Ltd Quinolone derivatives
US4138490A (en) 1975-03-20 1979-02-06 Imperial Chemical Industries Limited Analgesic compositions containing 1,2-dihydro-2-oxoquinol-4-ylpropionic acid derivatives
SU555119A1 (ru) 1975-05-19 1977-04-25 Предприятие П/Я Г-4913 Вулканизуема резинова смесь на основе полиизопренового каучука
LU77254A1 (es) 1977-05-04 1979-01-18
US4326055A (en) 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
US4234589A (en) 1979-09-24 1980-11-18 E. R. Squibb & Sons, Inc. Imidazolylethoxymethyl derivatives of 1,3-dioxolo quinolines
JPS5777676A (en) 1980-10-31 1982-05-15 Otsuka Pharmaceut Co Ltd Carbostyril derivative
DE3202100A1 (de) 1982-01-23 1983-08-04 Basf Ag, 6700 Ludwigshafen Substituierte benzoesaeure-4-hydroxyanilide, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
US4534979A (en) 1982-06-28 1985-08-13 Usv Pharmaceutical Corp. Polyene compounds useful in the treatment of psoriasis and allergic responses
US4427654A (en) 1982-07-27 1984-01-24 University Of Delaware Wound healing compositions and formulations
US4505852A (en) 1982-11-29 1985-03-19 Enzyme Systems Products 7-Amino-4-trifluoromethylquinolone derived substrates and method for determining enzymes and inhibitors
US4539134A (en) 1982-12-02 1985-09-03 Halliburton Company Methods and cleaning compositions for removing organic materials from metallic surfaces
PT79699B (en) 1983-12-22 1986-12-10 Pfizer Process for preparing quinolone inotropic agents
NZ212209A (en) 1984-05-29 1988-08-30 Pfizer Quinolone derivatives and pharmaceutical compositions
US4783549A (en) 1984-09-05 1988-11-08 L'oreal Benzonorbornene derivatives, processes for their preparation and medicinal and cosmetic compositions containing them
DE3434944A1 (de) 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen L-substituierte tetralinderivate, ihre herstellung und verwendung
FR2580277B1 (fr) 1985-04-15 1988-06-10 Oreal Nouveaux derives naphtaleniques a action retinoique, le ur procede de preparation et compositions medicamenteuse et cosmetique les contenant
LU86022A1 (fr) 1985-07-25 1987-02-04 Cird Derives aromatiques polycyliques,leur procede de preparation et leur application dans les domaines pharmaceutique et cosmetique
JPS62215581A (ja) 1986-03-18 1987-09-22 Koichi Shiyudo フラボンカルボン酸誘導体
FR2601670B1 (fr) 1986-07-17 1988-10-07 Cird Nouveaux derives bicycliques aromatiques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire et en cosmetique
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
FR2605626B1 (fr) 1986-10-27 1989-06-02 Oreal Nouveaux derives aromatiques bicycliques, leur procede de preparation et leur utilisation en cosmetique et en medecine humaine et veterinaire
US5081242A (en) 1986-12-22 1992-01-14 Ortho Pharmaceutical Corporation 6-benzoxazinyl- and 6-benzothiazinyl 2,3,4,5-tetrahydropyridazin-3-ones
GB8630702D0 (en) 1986-12-23 1987-02-04 Wellcome Found Quinoline compound
FR2614618B1 (fr) 1987-04-30 1989-07-07 Cird Derives heterocycliques polycycliques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire
EP0303418A3 (en) 1987-08-11 1990-11-07 Smithkline Beecham Laboratoires Pharmaceutiques Substituted indolones, useful in the treatment of heart or asthmatic diseases
LU87040A1 (fr) 1987-11-04 1989-06-14 Oreal Esters aromatiques polycycliques d'antibiotiques macrolidiques et lincosamidiques,leur procede de preparation et compositions pharmaceutiques et cosmetiques les contenant
US4981784A (en) 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US4874284A (en) * 1987-12-03 1989-10-17 New Jr James Truitt Kit for transporting all terrain vehicles
WO1989007441A1 (en) 1988-02-10 1989-08-24 The Regents Of The University Of California 6-amino-1,2-benzopyrone antitumorigenic agents and method
DE3810706A1 (de) 1988-03-25 1989-10-05 Schering Ag Substituierte cumarinderivate, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider wirkung
DE68916592T2 (de) 1988-06-23 1994-12-01 Agfa Gevaert Nv Für elektrophotographische Zwecke geeignetes photoempfindliches Aufzeichnungsmaterial.
GB8820174D0 (en) 1988-08-25 1988-09-28 Wellcome Found Quinoline compound
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
DE4036779A1 (de) 1990-11-17 1992-05-21 Basf Ag Verwendung von arylpolyencarbonsaeuren und ihren derivaten als lichtschutzmittel in kosmetischen zubereitungen
US5147844A (en) 1991-06-14 1992-09-15 Eastman Kodak Company Mixture on cyan and yellow dyes to form a green hue for color filter array element
FR2683818B1 (fr) 1991-11-14 1993-12-31 Adir Cie Nouveaux derives de 3-sulfonylamino-2-(1h)-quinoleinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE69333894D1 (de) 1992-04-22 2005-12-01 Ligand Pharm Inc Verbindungen mit Retinoid x rezeptorselektivität
CA2093577C (en) 1992-05-07 2006-01-03 Michael Klaus Alkyl or alkoxy substituted s-heterocyclic retinoids
NZ248794A (en) 1992-09-29 1995-01-27 Adir 3-carboxy-(and phosphonoxy-)alkatriene-substituted chromene derivatives and medicaments
JPH08506323A (ja) 1992-11-25 1996-07-09 ラ ホヤ キャンサー リサーチ ファウンデーション Ｒｘｒホモダイマー形成ならびに架橋二環式芳香族化合物および調節遺伝子発現におけるそれらの使用
WO1994015901A1 (en) 1993-01-11 1994-07-21 Ligand Pharmaceuticals Inc. Compounds having selectivity for retinoid x receptors
CA2153235C (en) 1993-01-11 2005-08-23 Marcus F. Boehm Compounds having selectivity for retinoid x receptors
US5455265A (en) 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5399586A (en) 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
AU1860995A (en) 1994-03-08 1995-09-25 Takeda Chemical Industries Ltd. Quinoline or quinazoline derivatives as anti-inflammatory agents, in particular for treating arthritis
FR2719041B1 (fr) * 1994-04-26 1996-05-31 Cird Galderma Nouveaux composés polyéniques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
MX9700778A (es) 1994-08-10 1997-05-31 Hoffmann La Roche Ligandos del receptor x del acido retinoico.
US5977125A (en) 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
US5968908A (en) 1994-12-19 1999-10-19 American Cyanamid Company Restricted 9-cis retinoids
IL116259A (en) 1994-12-19 2000-07-16 American Cyanamid Co Analogs of 9-cis retinoic acid and their use
US5696133A (en) 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
HUT78117A (hu) 1994-12-22 1999-11-29 Ligand Pharmaceuticals Incorporated Szteroid receptor modulátor kinolin- és kondenzált kinolinszármazékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
AU712187B2 (en) * 1994-12-30 1999-10-28 Ligand Pharmaceuticals Incorporated Novel trienoic retinoid compounds and methods
US6083977A (en) 1994-12-30 2000-07-04 Ligand Pharmaceuticals Incorporated Trienoic retinoid compounds and methods
ATE224900T1 (de) 1995-06-21 2002-10-15 Sod Conseils Rech Applic Camptothecinanaloge, verfahren zur ihrer herstellung, ihre verwendungals arzneimittel und diese enthaltende pharmazeutische zusammenfassungen
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
ES2190479T3 (es) 1995-10-06 2003-08-01 Ligand Pharm Inc Moduladores de rxr selectivos a dimeros y metodos para su uso.
EP0918774B9 (en) 1996-06-27 2002-04-10 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
FR2752837B1 (fr) * 1996-09-02 1999-11-12 Cird Galderma Nouveaux composes modulateurs des recepteurs hormonaux, les compositions les comprenant et leur utilisation en therapie
AU749810B2 (en) 1997-11-12 2002-07-04 Basilea Pharmaceutica Ag Treatment of T-helper cell type 2 mediated immune diseases
EP1077919A1 (en) 1998-05-11 2001-02-28 Novo Nordisk A/S New compounds, their preparation and use
US6147224A (en) 1998-10-01 2000-11-14 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
CA2366186C (en) * 1999-03-08 2007-05-15 Basilea Pharmaceutica Ag Retinoid antagonists and use thereof
AT407876B (de) 1999-04-30 2001-07-25 Georg Dr Uray Lumineszierende 4-trifluormethyl-2-chinolinone mit langwelliger uv-absorption und ihre verwendung

Also Published As

Publication number Publication date
JP2003529545A (ja) 2003-10-07
US20040049072A1 (en) 2004-03-11
WO2001019770A2 (en) 2001-03-22
AU7586600A (en) 2001-04-17
EP1216221A2 (en) 2002-06-26
CA2383565A1 (en) 2001-03-22
WO2001019770A3 (en) 2001-12-20
US6593493B1 (en) 2003-07-15
CO5200852A1 (es) 2002-09-27

Similar Documents

Publication Publication Date Title
PE20010647A1 (es) Moduladores de receptores de retinoide x (rxr) con perfil farmacologico mejorado
AR018917A1 (es) Compuestos derivados de adenosina que son agonistas en el receptor adenosina a1, proceso para su preparacion, composiciones farmaceuticas que los contienen.
PE20010645A1 (es) Compuestos espiro como antagonistas de los receptores del neuropeptido y
AR247213A1 (es) Preparacion de acido 7-¡(1-carboxi-3-fenilpropil)amino¿-3,4,6,7,8,12b-octahidro-6-oxopirido ¡2,1-a¿ o hexahidro-6-oxo-1h(1,4-tiazino¡3,4-a¿¡2¿-benzazepin-4-carboxilico, agentes hipertensivos.
AR003955A1 (es) Derivados de n-(indol-2-carbonil)-glicinamidas, procedimiento para su obtencion y composiciones que los contienen.
PE20020753A1 (es) Heteroaromaticos fusionados como activadores de la glucoquinasa
ECSP941135A (es) Antagonistas triciclicos de vasopresina de benzacepina
PE20010638A1 (es) Imidazo-5-il-aminas biciclicas, medicamentos que las contienen, su uso para la preparacion de medicamentos y procedimiento para su preparacion
ES2065324T3 (es) N-(piridinil)-1h-indol-1-aminas, un procedimiento para su preparacion y su uso como medicamentos.
PE29798A1 (es) Acetidinas
DK1189900T3 (da) Heterocykliske aminopyrrolidinderivater som melatonerge lægemidler
AR246962A1 (es) Procedimiento para preparar derivados alquilamino-alquilenicos de ciertos 2h-1-benzopiranos.
FI894061A0 (fi) Menetelmä lääkeaineina käyttökelpoisten , -disubstituoitujen N-sykloalkyylialkyylibentsyyliamiinien valmistamiseksi ja niiden synteesivälituotteita
PE27497A1 (es) Derivados de 1,5 benzodiazepina
DK0387618T3 (da) Hidtil ukendte 1,7-anellerede 1H-indol-2-carboxylsyre-N-(1,4-benzodiazepin-3-yl)amider
KR890000482A (ko) (8β)-1-알킬-6-(치환된) 에르 골린의 시클로알킬아미드
AR028743A1 (es) DERIVADOS DE N-TRIAZOLILMETIL-PIPERAZINA CON ACCIoN ANTAGONISTA DE RECEPTORES DE NEUROQUININA
PE51499A1 (es) Derivados de 5-aroilnaftaleno
RU2000109298A (ru) Производные 8-азабицикло[3.2.1]октан-3-метанамина в качестве лигандов рецепторов дофамина d2 и d3 и рецепторов серотонина 5ht14 b 5ht2
NO872832D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
AR035247A1 (es) Derivados de piperidinacarboxamida, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen
AR022797A1 (es) Benzoil indoles n-sustituidos como agentes estrogenicos
PE86698A1 (es) Derivados de indolina
ES2038159T3 (es) Procedimiento para preparar derivados sustituidos de 2-aminoacetamida.
AR002204A1 (es) Compuestos piridiniminil-1,2-bencisoxazoles y bencisotiazoles utiles como agentes para aliviar la disfuncion de la memoria, compuestos intermediarios,procedimientos de preparacion, composiciones que hacen uso de dichos compuestos e intermediarios.

Legal Events

Date Code Title Description
FC Refusal